Peer Review History
| Original SubmissionJune 30, 2022 |
|---|
|
PONE-D-22-18599Effect of human mobility restriction on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021)PLOS ONE Dear Dr. Hibiya, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Please note that we have needed three reviewers to decide on your manuscript, so we ask that you carefully consider the suggestions. Please note that citation suggestions will not influence the final decision on your manuscript. ============================== Please submit your revised manuscript by Jan 05 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Kovy Arteaga-Livias Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that [Figure 1] in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission: a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. The following resources for replacing copyrighted map figures may be helpful: USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/ The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/ Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/ Landsat: http://landsat.visibleearth.nasa.gov/ USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/# Natural Earth (public domain): http://www.naturalearthdata.com/. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: No Reviewer #3: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This manuscript uses time series data for vector-borne diseases in Japan to ask whether Covid-related mobility changes led to significant changes in vector-borne disease cases. The authors find a significant decrease in imported vector-borne diseases, particularly malaria. Most endemic diseases exhibited no significant change, except for SFTS and scrub typhus, which significantly increased. Estimating how behavioral changes connected to Covid-19 affected transmission of other diseases is important for planning for future pandemic and understanding drivers of vector-borne disease transmission. The authors use extensive data collected between 2016 and 2021 and examine several potentially relevant covariates. However, I do not think the current analyses and conclusions are appropriate for publication. In particular, I have questions about the appropriateness and robustness of the statistical methods used. Major: It is not clear from the methods, but it appears that the interrupted time series analysis was conducted by aggregating points across a year, meaning that there were four points in the pre-pandemic period and two points in the post-pandemic period, and extremely small sample size. The interrupted time series analysis also assumes a linear trend over time, but no information is provided to support this assumption. There is also not sufficient information provided about the coefficients returned from the ITSA and their significance to evaluate the results of this analysis. Additionally, the assumptions underlying this analysis require further justification. For example, there is often some lag in vector-borne disease transmission, so it’s unclear that the effects of Covid-related behavioral changes would be observed immediately. Although the analysis assumes stationarity in the pandemic period, the types and intensity of Covid-related behavioral changes may also have changed over the course of the 2020-2021 time period. It’s also not clear why the pre-pandemic period is defined as starting in 2016 and the pandemic period ends in 2021 for this analysis. Is this due to data access or a methodological decision? Is it accurate to assume stationarity across each of these periods? Covid may have also disrupted surveillance efforts and decreased access to healthcare, leading to a change in reporting rates. This effect could significantly influence your results, especially the static comparisons between pre and post-pandemic disease burden. This should be investigated directly (perhaps by comparing metrics that could serve as proxies for reporting rate, like test positivity and non-Covid medical appointments in the pre and post-pandemic periods) as it could significantly impact the study’s findings. The Olympic Games are mentioned several times, but it’s unclear what the hypothesized effect is and what VBD and Covid precautions (if any) were taken while the games happened. It may even be worth considering whether the Olympic Games themselves constitute another event that may have separately altered VBD transmission. Line 356 states that there was no “no significant increase” during the Olympic Games, but doesn’t include an analysis to support this claim. In general, the manuscript considers several diseases and covariates, which can make the paper difficult to follow. Better organization throughout and a schematic figure that illustrates the key questions/proposed mechanisms could help to guide the reader. Below, I mentioned a few cases where analyses and their corresponding hypotheses are not in the introduction, as well as strong causal claims that are made without sufficient evidence. Such claims should be supported with either additional analyses or references to other studies. Minor: line 19: “common” should be “domestic” or “endemic” (and be consistent throughout) line 22: clarify that the analysis was conducted using data for Japan at the regional level line 33: change semicolon to period line 44: were there restrictions on domestic travel? Please also include discussion of when restrictions were implemented and how long they were in place line 45: remove “unnecessary” line ~ 49: You should also mention that Covid restrictions could lead to increases in vector-borne diseases by disrupting medical services and vector control campaigns. Line 59: mention Covid impacts on trade here Line 63: explain why you would expect a difference between short and long-term effects Line 65: “since the COVID-19 pandemic” – arguably, the pandemic is ongoing, so it may make more sense to say “since the COVID-19 pandemic began” In the introduction, you should also discuss domestic mobility and where humans tend to come into contact with the different types of vectors to develop hypotheses for how diseases may have changed during the pandemic based on mobility changes. In the introduction, you should introduce the ideas behind the estimated infected areas analysis, gender, and age-specific incidence analysis, why you think the distribution may have changed under Covid, and the hypothesized direction of that change. Throughout the manuscript, you use the term “mobility restriction” generally, but it would be useful to clarify when you’re discussing bans on international travel vs reduction in local travel, as the expected outcomes differ. Line 122 – what percent of people riding bullet trains are commuter (are you excluding a significant proportion of train riders from your analysis?) Line 131-136 – is there precedent for using passenger-kilometer and ton-kilometer in this manner as metrics for passenger/cargo transport? Please cite other studies that use them. Line 150 – “estimated regions of infection” please explain in greater detail what this means and how it was determined. Is it based on individual follow-up for each case? Line 159 – you should also mention in this paragraph that you have data on whether particular cases of each disease were transmitted locally or imported and explain how that information was initially assessed. Line 174 – clarify that you are comparing annual burden in either period (otherwise it’s confusing to compare a 4 vs 2 year period) Line 177-179 – is this part of the analysis described in the previous paragraph? If so, make that clear Line 205 – clarify it was “on the rise” prior to the pandemic’s beginning Line 205-235 – a lot of the information given here feels extraneous, which makes it difficult to keep track of the general trends that you’re describing in this section Fig 3 – add titles and y-axis labels to each of the plots to make it easier to understand what each panel is plotting All tables – note any significant differences in bold Line 250 – “an overall decline” -> “fewer cases” Line 256 – “statistically” -> “statistical” Line 256-258 – “malaria showed significantly…Japanese spotted fever” need more detail here. What were the estimated slopes and intercepts? It also seems like you’re missing discussion of dengue and Japanese spotted fever. Lines 282 and throughout – try to avoid using “significant” if you’re not referring to the result of a statistical analysis Fig 4 – It’s inconsistent to have an average for 2016-2019 and then the yearly values for 2020 and 2021. Can you show just individual years or just averages for all of them (although that may get a bit crowded)? I also think you can move some of the panels to the supplement and just focus on a few of the disease that showed the most interesting/significant trends with this figure. Table 3 - for pre-pandemic SFTS in West Japan, it looks like the percentage is wrong (should be 99.7) Line 320 – “was suppressed” I don’t think you actually showed this statistically. If so, please reference the relevant analysis. I would also change the order of this to lead with your most important findings. Line 322 – “Maralia” -> “malaria” Line 339 – “was only 0.87% of that in 2019” this is quite low, so make sure the number is correct and also cite your source/the table you’re referencing for this. Line 347-355 This paragraph is confusing. What do you mean by saying trade is “currently saturated and unlikely to increase/decrease?” How does it compare to the pre-pandemic baseline or the time period observed in the study? “A rapid epidemic would have occurred…” is an extremely strong claim, and there are no analyses or sources here to support it. Line 357 – “We attribute this” you don’t have sufficient evidence to make this causal claim Line 363 – “However, the number of patients…” -> “However, a change in the number of patients” Line 367 – “travel for tourism purposes” explain more why you think this would have changed the distribution of travel and provide sources. Line 378-383 – too much detail provided here about someone else’s study Line 398 – “ these may be plausible” please try to find additional sources to support this hypothesis. Have other people found similar trends? Line 404 – “ humans are not an infectious source” – what does this mean? Humans can’t transmit back to the vector? Line 406 – “suspected region of infection” relate this back to a specific table and cite it Line 423 – “various studies” -> cite the studies you’re referencing Line 443 – “new residents in rural areas” - do regional patterns bear this out? What other data and tables from the study can you cite to support this? Line 461 – “new infectious diseases such as COVID-19” this sentence is confusing because Covid isn't a vector-borne disease Reviewer #2: In this study, the authors examined the impact of mobility restriction on vector-borne diseases during the COVID-19 pandemic in Japan through a descriptive epidemiological study. They collected both mobility data and several typical vector-borne diseases data. They performed a simple interrupted time series analysis. I have a few comments: 1. In line 41, “Wuhan (Zhejiang Province, People's Republic of China)”. This might be corrected as “Wuhan (Hubei Province, People's Republic of China)”. 2. Vector-borne diseases have a strong seasonality and subject to the level of population immunity gained through previous infections [ref 24]. The authors may wish to account for these confounding factors. Otherwise, it is difficult to understand if the observed pattern in incidence is due to restrictions or other factors. 3. In line 174, “estimated number of infections”. Could you explain how the number of true infections was estimated in this study? Reviewer #3: This manuscript, “Effect of human mobility restriction on vector-borne diseases during the COVID-19 pandemic in Japan”, provides a nice summary of how the incidence of imported and domestic vector-borne disease cases have shifted during the COVID-19 pandemic period in pandemic compared to the pre-pandemic period. The analysis includes all vector-borne diseases that are nationally notifiable, which allows the authors to look at broader trends that might be missed in an analysis of a single pathogen. The manuscript is labeled as a descriptive epidemiological study, however, I believe that the statistical analyses that are conducted need improvement. In addition, some of the results need to be more clearly presented as in some sections of the Results and Discussion it is stated that several of the domestic diseases increased during the pandemic, but then in another section it will say that the same diseases did not experience a statistically significant change in incidence. If this is due to differences in the results of the different statistical tests (t-test vs. ITSA) then which test is being referred to needs to be clearly stated. Major comments 1. No values are reported for any of the statistical analyses (e.g., the t-score and p-values for the t-tests, or p-value and coefficient estimates for ITSA). It is also not clear which analysis (the t-test or ITSA) is being referenced in some of the Results (e.g., on lines 241-244), including the appropriate statistical values will make it clearer which test is being mentioned. 2. For the Interrupted Time Series Analyses (ITSA), it is not clear whether the results presented are for significant changes in the level or trend pre- and post-pandemic. Both the Methods and Results sections need to specify which effect is being reported. In addition, because there are only four pre-pandemic data points, and only 2 pandemic data points, testing for changes in trends would be statistically inappropriate. There are also doesn’t appear to be a clear scientific reason why you would want to test for a change in the trend between the two time periods. The Methods section should also mention that the ITSA was conducted using annual incidence (as opposed to the t-test which mentions using weekly incidence data). 3. It is also not clear whether the ITSAs were carried out separately for each disease or if multiple diseases were modeled as part of a multiple-group comparison. I assume that each disease was modeled separately, but line 185 refers to “multiple-group ITSA”, which would imply that the authors were also comparing the response of different diseases to the pandemic “intervention”. This section needs clarification one way or the other, and if a multiple-group analysis was conducted, the reasons for such a choice should be articulated. 4. In multiple sections (Abstract, Results, and Discussion) there are contrasting statements regarding whether certain diseases increased or stayed the same during the pandemic compared to the pre-pandemic period. For example, line 31-33 of the abstract says that SFTS, scrub typhus, and Japanese spotted fever remained similar and then that SFTS and scrub typhus increased significantly in the very same sentence. Minor comments This study might benefit from the inclusion of cell-phoned derived mobility data. For example, Google has made data available on visits to multiple types of locations (https://www.google.com/covid19/mobility/). This could be an additional metric to show how movement rates changed in 2020 and 2021. In particular, one metric included by Google is visits to “parks and other natural areas”, which is relevant for several of the vector-borne diseases as mentioned in the Discussion section. Line 34 – “pan-endemic”: I assume this should be “pandemic”? Line 154-55: Japanese encephalitis is missing from this list of domestic vector-borne diseases included in the study. Line 178 – reference to Table S4 is to the incorrect table Table 1 is never referenced in the body of the text. The global incidence of several of the considered diseases, particularly Zika and chikungunya, was not stable from 2016-2019 before the COVID-19 pandemic. Zika incidence decreased from 2016-2019 as the epidemic in Latin America subsided. There should be some mention in the Discussion section that global trends might also influence incidence rates for imported diseases. Lines 257-58 – This sentence is incomplete. Lines 268-279 – In the “Estimated infected areas of imported infectious diseases” subsection of the Results, the word “in” needs to be replaced with “from” in multiple sentences. As in “cases were reported in Asia only” should be changed to “cases were reported from Asia only”. Lines 275-277 – 81.1% of cases from Asia is not significantly more common than 87.5% of cases. Table 3 – The first part of “Relapsing fever” is missing Line 322 – Malaria is spelled wrong Line 372 – The start of the “Domestic infectious diseases” subsection of the Discussion discusses how SFTS, scrub typhus, and spotted fever showed no apparent decrease during the pandemic period. It is only several paragraphs later that it is mentioned that these 3 diseases, plus Lyme and relapsing fever, were actually higher during the pandemic period. It makes more sense to mention the increase first rather than simply say that they didn’t decrease. Line 449 – Should ‘exclude’ be ‘include’? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-22-18599R1Effect of non-coercive human mobility restrictions on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021)PLOS ONE Dear Dr. Hibiya, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review Please submit your revised manuscript by Apr 23 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Kovy Arteaga-Livias Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have made significant revisions to the manuscript to justify model assumptions and hypotheses. In particular, data on healthcare visits suggest that limited access may not be an important source of bias in the analysis and mobility data help to illustrate why 2020-2021 was defined as the pandemic period. The paper presents interesting analyses regarding how and why nonpharmaceutical interventions in Japan may have impacted VBD transmission. A few minor revisions, listed below, may help to provide further clarity. Given the amount of different analyses and dataset in this paper, additional structuring and explanation to signpost the different components may be helpful. For example, the final paragraph of the introduction could contain a brief list of the research questions or parts of the manuscript. As different data sources are introduced throughout the methods section, please provide a brief explanation of why they were collected (e.g., "the number of returnees to Japan…was examined to understand how travel impacts etc"). Additionally, clarify that restriction in access to healthcare was considered (line 222) to understand whether underascertainment may have biased findings. The introduction should mention all analyses conducted, but currently does not clearly state the analysis that will be conducted on suspected region of infection. Although the revised title is helpful to indicate moderate behavior restriction, "voluntary" may be more clear than "non-coerceive." Line 68: The explanation provided in the discussion for potential sex differences is employment, but the hypothesis provided here involves "fear and anxiety." The suggested mechanism(s) should be consistent throughout. Line 246: "our country" -> Japan Line 248-50: The notation of giving the percentage with the smallest magnitude is a bit confusing. These values may be removed. Table 1: There appear to be an errors in this table. For example, no cases of Eastern equine encephalitis were reported in either period but a 55% reduction is given, but dengue cases decreased and are listed as 0% change. Providing values for VBDs with no reported cases also appears extraneous and may make the table more difficult to read. These rows may be removed and a footnote may be used to list diseases with no reported cases. Line 285: "infected area" -> change to "suspected region of infection" as this is more clear Line 285-94: The presentation and interpretation of the percentages here are unclear and potentially misleading. For example, line 290-1 says "the prevalence of dengue was also common in Asia (81.1%)," which I initially read to mean that 81.1% of people in the region were infected. Line 336: "relevant factors" -> be more specific about the eliminated factors Line 354: "may have had a significant impact on the incident" -> can this statement be supported using evidence from Table 3? Line 358: "current Europe" -> unclear what this means, please rephrase Line 373: "unlikely to have been affected" -> please provide further justification for this claim Line 407-415: The information provided regarding fever and other clinical symptoms of the different VBDs appears to be addressing whether VBDs may be misdiagnosed as Covid, but the connection is unclear. Please provide additional interpretation of these results or remove them. Line 422: "age and sex were influenced by other factors" -> the direction of the hypothesized relationship is incorrect here. Figure 4: The conceptual figure to indicate different covariates that may be relevant depending on the disease helps to organize the analysis, but the Venn Diagram format may be unnecessary to communicate this information. The figure could be improved by selecting a different format (perhaps a table), giving examples of specific covariates that fall under each covariate that were considered in the paper. If possible, it may also be helpful to include information about the hypothesized or estimated direction of the relationship. Reviewer #2: The authors have addressed all the comments in previous review. My pleasure to recommend its acceptance. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Lin Wang ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Effect of voluntary human mobility restrictions on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021) PONE-D-22-18599R2 Dear Dr. Hibiya, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Kovy Arteaga-Livias Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have done an excellent job addressing reviewer questions. I recommend its acceptance for publication. Two small additional recommendations for clarity are provided here. Please ensure that the "not reported" labeled is applied consistently in Table 1 (epidemic typhus and tularemia should receive this label). The table could also be sorted by the % change per year column so that rows with cases reported are grouped together, making it easier for the reader to focus on potential diseases of interest. The language about changes in distribution of suspected regions of infection (lines 314-323) could also be further clarified. Rather than making statements about the relative prevalence in different regions, this section is actually comparing the relative share of total imported cases suspected to be attributable to travels from a given region. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ********** |
| Formally Accepted |
|
PONE-D-22-18599R2 Effect of voluntary human mobility restrictions on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021) Dear Dr. Hibiya: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Kovy Arteaga-Livias Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .